A Phase 1 double-blind, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety and tolerability of single ascending and multiple doses of aficamten in healthy Japanese and Caucasian participants
Latest Information Update: 14 Aug 2024
At a glance
- Drugs Aficamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Pharmacokinetics
Most Recent Events
- 08 Aug 2024 According to a Cytokinetics media release, company initiated a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian participants. We expect to continue enrollment throughout 2024.
- 19 Jun 2024 New trial record
- 17 Jun 2024 According to Cytokinetics media release, first patient has been dosed in this trial.